← Leaderboards
Koichi Yuki
Boston Children'S Hospital
$6,395,469
Attributed
$6,883,594
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $991.2K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,883,594 · 8
By mechanism
R01$3,983,948 · 3
R21$1,949,750 · 4
K08$949,896 · 1
Top collaborators
- Sophia Koutsogiannaki3 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Hidde L Ploegh$43,368,874
- Sophie-Charlotte Hofferberth$125,662
- Sophia Koutsogiannaki$488,125
Others in their field
Top investigators on “Neutrophil”
- Charles Nicholas Serhan · Brigham And Women'S Hospital$23,875,763
- Hongbo R Luo · Children'S Hospital Boston$23,323,359
- Tanya N. Mayadas · Brigham And Women'S Hospital$21,795,639
- Victor Nizet · University Of California, San Diego$21,031,691
- J. Edwin Blalock · University Of Alabama At Birmingham$19,196,735
- Robert Fairchild · Cleveland Clinic Lerner Com-Cwru$18,658,323
Research focus
NeutrophilMortalityCell Adhesion MoleculesInfectionCellsFutureImmuneBindingOperative Surgical ProceduresMediatingIn VitroIn VivoReportingExperimental StudyPhagocytosisAnestheticsLeadGeneral AnesthesiaIncidenceSepsisLigandsMorbidity - Disease RateHigh RiskPerioperative
Grant awards (23)
Unravelling the role of aDb2 as a novel complement receptor in lung injury$489,500
R21 · FY2025 · AI
CD11c as a novel target to improve neutrophil effector functions and sepsis outcome$381,984
R01 · FY2025 · GM · contact PI
CD11c as a novel target to improve neutrophil effector functions and sepsis outcome$386,433
R01 · FY2024 · GM · contact PI
CD11c as a novel target to improve neutrophil effector functions and sepsis outcome$389,400
R01 · FY2023 · GM · contact PI
The role of damage-associated molecular patterns in perioperative morbidities and mortalities of pediatric congenital heart diseases$221,250
R21 · FY2023 · HD · contact PI
Surgical site infections and the role of anesthesia and bacterial ion transporters$339,232
R01 · FY2022 · GM · contact PI
The role of damage-associated molecular patterns in perioperative morbidities and mortalities of pediatric congenital heart diseases$265,500
R21 · FY2022 · HD · contact PI
Optimization of anesthetic/sedative regimen for pulmonary pathophysiology in cystic fibrosis patients$221,250
R21 · FY2022 · AI · contact PI
Surgical site infections and the role of anesthesia and bacterial ion transporters$345,199
R01 · FY2021 · GM · contact PI
Optimization of anesthetic/sedative regimen for pulmonary pathophysiology in cystic fibrosis patients$265,500
R21 · FY2021 · AI · contact PI
Neutrophil-mediated multiple organ dysfunction during sepsis$221,250
R21 · FY2021 · HD · contact PI
Surgical site infections and the role of anesthesia and bacterial ion transporters$371,700
R01 · FY2020 · GM · contact PI
The impact of anesthetic selection on sepsis outcome and its mechanism$354,000
R01 · FY2020 · GM · contact PI
Neutrophil-mediated multiple organ dysfunction during sepsis$265,500
R21 · FY2020 · HD · contact PI
The impact of anesthetic selection on sepsis outcome and its mechanism$354,000
R01 · FY2019 · GM · contact PI
The impact of anesthetic selection on sepsis outcome and its mechanism$354,000
R01 · FY2018 · GM · contact PI
The impact of anesthetic selection on sepsis outcome and its mechanism$354,000
R01 · FY2017 · GM · contact PI
The impact of anesthetic selection on sepsis outcome and its mechanism$354,000
R01 · FY2016 · GM · contact PI
Immunomodulatory mechanism of volatile anesthetics$159,336
K08 · FY2016 · GM · contact PI
Immunomodulatory mechanism of volatile anesthetics$197,640
K08 · FY2015 · GM · contact PI
Immunomodulatory mechanism of volatile anesthetics$197,640
K08 · FY2014 · GM · contact PI
Immunomodulatory mechanism of volatile anesthetics$197,640
K08 · FY2013 · GM · contact PI
Immunomodulatory mechanism of volatile anesthetics$197,640
K08 · FY2012 · GM · contact PI